Upstream Bioprocessing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Upstream Bioprocessing Market is expected to register a CAGR of 5.5% during the forecast period. This is attributing to the rising adoption of single-use upstream bioprocessing, commercial success and rising demand for biotherapeutics and rising competition among the market vendors. Upstream bioprocessing is very important in research activities for the development of biosimilars, therapeutic peptide, and monoclonal antibodies. Moreover, the upstream bioprocessing is contamination-free, safe, efficient production which aids the demand of these process further propels the market. Furthermore, the growing awareness and implementation of the Process Analytical Technology (PAT) strategy to monitor, analyze and optimize cell culture production process through various parameters such as real-time nutrient analysis and inline monitoring of cell density also helps in increasing the market. This technology helps in critical quality attributes of the upstream bioprocessing and further improves the productivity of the process and boost the market. However, the high cost of overall processing with operational challenges pertaining to the process may hamper the market.

Key Market Trends

Bioreactors/ Fermentors in Upstream Bioprocessing is Expected to Witness a Healthy Growth in Future.

Bioreactors/ Fermenters in upstream bioprocessing are expected to witness a healthy growth in the future due to the wide application in small and large bioproduction. The high usage of Bioreactors with its new development in terms of safety, cost-effectiveness is also driving the market. Moreover, cell culture products also show a lucrative opportunity in the market as there is an increasing demand for high titer producing a cell culture.

In addition, with the growing number of R&D expenditure worldwide and several advantages related to upstream processing results in driving the overall market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Upstream Bioprocessing market due to increasing R&D expenditure, the presence of major market players, the increasing burden of chronic diseases, well-established healthcare infrastructure. Moreover, increasing demand for proteins for the treatment of several diseases like lymphoma, rheumatoid arthritis and diabetes wherein specific proteins can be produced through upstream bioprocessing further drive the market in this region.

Competitive Landscape

The Upstream Bioprocessing Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Thermo Fisher Scientific Inc., GE Healthcare, Corning, Inc., Merck KGaA, Eppendorf AG, Sartorius AG, Boehringer Ingelheim GmbH, Danaher Corporation, Applikon Biotechnology and CellGenix GmbH.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support